1. Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy.
- Author
-
Balayssac D, Cayre A, Ling B, Maublant J, Penault-Llorca F, Eschalier A, Coudoré F, and Authier N
- Subjects
- Analgesics, Opioid administration & dosage, Animals, Benzazepines administration & dosage, Brain drug effects, Brain metabolism, Cisplatin, Drug Synergism, Ganglia, Spinal drug effects, Ganglia, Spinal metabolism, Male, Morphine administration & dosage, Pain chemically induced, Pain Measurement, Pressure, Quinolines administration & dosage, Rats, Rats, Sprague-Dawley, Sciatic Nerve drug effects, Sciatic Nerve metabolism, Spinal Cord drug effects, Spinal Cord metabolism, Technetium Tc 99m Sestamibi, ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors, Analgesics, Opioid pharmacology, Benzazepines pharmacology, Morphine pharmacology, Pain drug therapy, Quinolines pharmacology
- Abstract
Pain from anticancer drugs-induced neuropathies is difficult to treat and can significantly alter the patient's quality of life. These neuropathies are considered relatively resistant to conventional analgesic drugs (opioids). Opioids are also P-glycoprotein substrates and it has been demonstrated that the P-glycoprotein is linked to the integrity of blood-brain barrier protecting the nervous system. Previous works presented an increase of P-glycoprotein in vincristine- and cisplatin-induced neuropathy which could potentially decrease opioid efficiency. To test this hypothesis, the efflux inhibition of P-glycoprotein and the antinociceptive effect of morphine were assessed in normal and cisplatin-induced neuropathic rats after the administration of the P-glycoprotein inhibitor (R101933). R101933 (20 mg/kg) inhibited significantly the efflux transporter under the condition of the study and had no analgesic effect. Nociceptive thresholds were measured by the paw pressure test. R101933 (20 mg/kg) enhanced antinociceptive activity of morphine (0.5 mg/kg) to a maximum of +58% and +35%, respectively compared with control animals and animals treated by morphine alone (0.5 mg/kg). R101933 increased morphine (2 mg/kg) antinociceptive activity to a maximum of +105% compared with control animals and to a maximum of +41% compared with morphine alone (2 mg/kg). This study demonstrated that cisplatin-induced neuropathy may present a particular pathophysiology with a multidrug resistance, of the central nervous system, to analgesics. This resistance can be blocked by a P-glycoprotein inhibitor which may enhance analgesia of low doses of morphine.
- Published
- 2009
- Full Text
- View/download PDF